Proteomic Profiling of Serum-Derived Exosomes from Ethnically Diverse Prostate Cancer Patients

Cancer Investigation

Volumn 34, Issue 1, 2016, Pages 1-11

  Turay, David ^a,b   Khan, Salma ^a,b   Diaz Osterman, Carlos J ^a,b   Curtis, Matthew P ^b   Khaira, Balreet ^b   Neidigh, Jonathan W ^b   Mirshahidi, Saied ^b   Casiano, Carlos A ^a,b   Wall, Nathan R ^a,b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

Biomarker; Early detection; Exosome; Health disparity; Prostate cancer; Proteome

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATAXIN; CELL PROTEIN; CERULOPLASMIN; COMPLEMENT; COMPLEMENT FACTOR H; FIBRINOGEN; FIBRONECTIN; GLUTATHIONE TRANSFERASE; HAPTOGLOBIN; IROQUOIS HOMEOBOX PROTEIN 5; KERATIN; LEUCINE RICH ZIPPER CONTAINING 4; MACROGLOBULIN; MINICHROMOSOME MAINTENANCE PROTEIN 5; MITOCHONDRIAL TUMOR SUPPRESSOR 1 ISOFORM 4; NASOPHARYNGEAL EPITHELIUM SPECIFIC PROTEIN; PREGNANCY ASSOCIATED ALPHA2 GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; SERUM AMYLOID P; TRANSFERRIN; TRINUCLEOTIDE REPEAT CONTAINING 6B; UBIQUITIN; UNCLASSIFIED DRUG; PROTEOME; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER THERAPY; CELL COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE SEVERITY; ETHNICITY; EXOSOME; HUMAN; MALE; MEMBRANE VESICLE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEOMICS; BIOLOGY; BLOOD; CASE CONTROL STUDY; ETHNIC GROUP; METABOLISM; PROCEDURES; PROSTATE TUMOR;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; ETHNIC GROUPS; EXOSOMES; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS;

EID: 84956821895     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2015.1081921     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin 2014; 64 (1): 9-29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61 (2): 69-90.
3. Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 2014; 120 (10): 1532-1539.
4. Tindall EA, Monare LR, Petersen DC, van Zyl S, Hardie RA, Segone AM, et al. Clinical presentation of prostate cancer in black South Africans. Prostate 2014; 74 (8): 880-891.
5. Smith MR, Klotz L, van der Meulen E, Colli E, Tanko LB. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011; 186 (5): 1835-1842.
6. Verma A, St Onge J, Dhillon K, Chorneyko A. PSA density improves prediction of prostate cancer. Canad J Urol 2014; 21 (3): 7312-7321.
7. Bryant RJ, Lilja H. Emerging PSA-based tests to improve screening. Urolog Clin North America 2014; 41 (2): 267-276.
8. Darwish-Yassine M, Berenji M, Wing D, Copeland G, Demers RY, Garlinghouse C, et al. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. J Cancer Survivorship 2014; 8 (1): 121-130.
9. Kardasevic A, Delic-Redzepagic E. Qualitative approach and treatment of patients with prostate cancer in cantonal hospital bihac during two years period. Materia Socio-Medica 2014; 26 (1): 59-61.
10. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomark Prev 2014.
11. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013; 190 (2): 389-398.
12. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing ? J Clin Oncol 2011; 29 (4): 464-467.
13. Faraday M, Hubbard H, Kosiak B, Dmochowski R. Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU Int 2009; 104 (3): 294-297.
14. Johnstone RM. Exosomes biological significance: A concise review. Blood Cells Mol Dis. 2006; 36 (2): 315-321.
15. Khan S, Bennit HF, Wall NR. The emerging role of exosomes in survivin secretion. Histol Histopathol 2015; 30 (1): 43-50.
16. Khan S, Jutzy JMS, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 2011; 16: 1-12.
17. Aspe JR, Diaz Osterman CJ, Jutzy JM, Deshields S, Whang S, Wall NR. Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant. J Extracell Vesicles 2014; 3.
18. Asuncion Valenzuela MM, Castro I, Gonda A, Diaz Osterman CJ, Jutzy JM, Aspe JR, et al. Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase. OncoTargets Ther 2015; 8: 495-507.
19. Valenzuela MM, Ferguson Bennit HR, Gonda A, Diaz Osterman CJ, Hibma A, Khan S, et al. Exosomes Secreted from Human Cancer Cell Lines Contain Inhibitors of Apoptosis (IAP). Cancer microenviron 2015.
20. Properzi F, Logozzi M, Fais S. Exosomes: the future of biomarkers in medicine. Biomark Med 2013; 7 (5): 769-778.
21. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 2011; 59 (5): 823-831.
22. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG. Are multiple markers the future of prostate cancer diagnostics ? Clin Biochem 2004; 37 (7): 519-528.
23. Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243-246.
24. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 2010; 37 (1): 131-141, X.
25. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.
26. Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PloS One 2012; 7 (10): e46737.
27. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal like vesicles are present in human blood plasma. Int Immunol 2005; 17: 879-887.
28. Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 2003; 278: 20083-20090.
29. Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994; 5 (11): 976-989.
30. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20 (18): 3551-3567.
31. Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004; 20 (9): 1466-1467.
32. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74 (20): 5383-5392.
33. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75 (17): 4646-4658.
34. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, et al. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Brit J Cancer 2009; 100: 1073-1086.
35. Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, et al. Can urinary exosomes act as treatment response markers in prostate cancer ? J Transl Med 2009; 7: 4.
36. Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ochieng J. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PloS One. 2011; 6 (9): e24234.
37. Mazzola CR, Ghoneim T, Shariat SF. Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer. Prog Urol 2011; 21 (1): 1-10.
38. Welsh JB, Sapinoso LM, Kern SG., Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003; 100 (6): 3410-3415.
39. Lin Q, Tan HT, Lim HS, Chung MC. Sieving through the cancer secretome. Biochimica et biophysica acta 2013; 1834 (11): 2360-2371.
40. Park JA, Sharif AS, Tschumperlin DJ, Lau L, Limbrey R, Howarth P, et al. Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. J Allergy Clin Immunol 2012; 130 (6): 1375-1383.
41. Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 2013; 13 (10-11): 1672-1686.
42. Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell proteomics 2013; 12 (2): 343-355.
43. Nguyen HH, Takata R, Akamatsu S, Shigemizu D, Tsunoda T, Furihata M, et al. IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. Hum Mol Gen 2012; 21 (9): 2076-2085.
44. Ye H, Pungpravat N, Huang BL, Muzio LL, Mariggio MA, Chen Z, et al. Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma. Cancer Genet Cytogen 2007; 176 (2): 100-106.
45. Tao S, Wang Z, Feng J, Hsu FC, Jin G, Kim ST, et al. A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. Carcinogenesis 2012; 33 (3): 598-603.